louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05723978: Selective Extended Dissection in Different Types of Pancreatic Head Cancer: A Retrospective Cohort Study.
Official title: Selective Extended Dissection in Different Types of Pancreatic Head Cancer: A Retrospective Cohort Study.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Carcinoma, Pancreatic Ductal
Lead sponsor: Tianjin Medical University Cancer Institute and Hospital
Sponsor class: OTHER
First posted: 2023-02-13
Enrollment: 520
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients diagnosed as resectable pancreatic cancer were pathologically diagnosed as PDAC after surgery

Brief summary: Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant tumor with relatively poor survival. Surgery is the first choice for the treatment of patients with early pancreatic cancer. However, the surgical approach and the extent of resection for patients with pancreatic cancer are controversial at present.

The investigators optimized the procedure of standard pancreaticoduodenectomy to selective extended dissection (SED), which is based on the extra-pancreatic nerve plexus (PLX) potentially invaded by tumor. The investigators retrospectively analyzed the clinicopathological data of patients with pancreatic adenocarcinoma who underwent radical surgery in our center from 2011 to 2020. Patients who underwent standard dissection (SD) were matched 2:1 to those who underwent SED using propensity score matching (PSM). The log-rank test and cox regression model were used to analyze survival data. In addition, statistical analyses were performed for the perioperative complications, postoperative pathology and recurrence pattern.


Eligibility criteria: Inclusion Criteria:

- 1) Patients diagnosed as resectable pancreatic cancer were pathologically diagnosed as PDAC after surgery.

2) Patients received radical surgery (R0) and had complete photos or videos of the operation.

Exclusion Criteria:

- 1) The operation records as well as related photo or video data could not reflect the surgical approach and the extent of resection.

2) Patients with incomplete clinical, pathological, imaging and follow-up information.

Primary outcomes:
measure: Disease-free survival (DFS)
timeFrame: From the day the patient received surgery to the time the patient was diagnosed with postoperative recurrence, assessed up to 36 months.
Secondary outcomes:
Other outcomes:
Locations:
city: Tianjin
country: China
facility: Tianjin Medical University Cancer Institute and Hospital
state: Tianjin
Study officials:
References:
Clinical trial NCT02044978: Initial Fixation of Bisphosphonate-coated Dental Implants
Official title: Initial Fixation of Bisphosphonate-coated Dental Implants
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Pre-integration Failure of Dental Implant
Lead sponsor: University Hospital, Linkoeping
Sponsor class: OTHER
First posted: 2014-01-24
Enrollment: 16
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: 16 patients will be included. Each patient receives 2 dental implants. One of them is coated with a drug, zoledronate, to improve fixation. Fixation is measured by vibration resonance frequency analysis at insertion and 2, 4, 6 and 8 weeks after insertion.The 2 implants in each patient are compared. We expect to find an early improvement (higher resonance frequency) in the coated implant.

Detailed description: The zoledronate is linked to the titanium implant surface via a nanolayer of crosslinked fibrinigen. Resonance frequency is measured with standard clinical equipment (Ostell apparatus).

Eligibility criteria: Inclusion Criteria:

Need for dental implant in upper jaw. CTscan showing at least 6 mm bucco-lingual thickness. Generally healthy

Exclusion Criteria:

Drugs or conditions that influence or are thought to influence bone healing, such as bisphosphonates, corticosteroids, other oral pathologies, severe autoimmune diseases, cancer. Osteoporosis is not cause for exclusion.

Primary outcomes:
measure: Vibration frequency ratio
timeFrame: 4 and 6 weeks
Secondary outcomes:
measure: Marginal resorption
timeFrame: 8 weeks
measure: Vibration: area under the curve
timeFrame: 2-8 weeks
Other outcomes:
Locations:
city: Linköping
country: Sweden
facility: Käkcentralen
city: Linköping
country: Sweden
facility: Tandläkarhuset
Study officials:
References:
Clinical trial NCT02418078: Retrospective Analysis of the Geriatric Patients Underwent Unilateral Inguinal Herniorrhaphy
Official title: Retrospective Analysis of the Geriatric Patients Underwent Unilateral Inguinal Herniorrhaphy at Our Institution
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Inguinal Hernia
Lead sponsor: Diskapi Teaching and Research Hospital
Sponsor class: OTHER
First posted: 2015-04-16
Enrollment: 370
Sex: ALL
Minimum age (years): 19
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: patients with a unilateral inguinal hernia

Brief summary: The aim of this study is to compare the geriatric patients with the non-geriatrics undergoing outpatient unilateral herniorrhapy in terms of local anesthesia, sedation, recovery and early morbidity.

Detailed description: A retrospective data analysis will be conducted and the patient records will be evaluated for patient characteristics local anesthesia, sedation, recovery and early morbidity.

Eligibility criteria: Inclusion Criteria:

patients with a unilateral inguinal hernia undergoing herniorrhaphy

Exclusion Criteria:

none

Primary outcomes:
measure: discharge time
timeFrame: postoperative 2 hours
measure: discharge delay
timeFrame: postoperative 2 hours
measure: local anesthetic doses
timeFrame: intraoperative
measure: sedative doses
timeFrame: intraoperative
Secondary outcomes:
measure: complications (hypertension, tachycardia, bradycardia, hypotension, nausea, vomiting)
timeFrame: intraoperative
measure: early morbidity
timeFrame: postoperative 2 hours
measure: morbidity
timeFrame: postopative 1 week
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Dıskapı TRH
Study officials:
affiliation: Diskapi Teaching and Research Hospital
name: Hakan Kulacoglu, Prof
role: STUDY_DIRECTOR
References:
citation: Mattila K, Hynynen M; Intensium Consortium Study Group. Day surgery in Finland: a prospective cohort study of 14 day-surgery units. Acta Anaesthesiol Scand. 2009 Apr;53(4):455-63. doi: 10.1111/j.1399-6576.2008.01895.x. Epub 2009 Feb 23.
citation: Majholm B, Engbaek J, Bartholdy J, Oerding H, Ahlburg P, Ulrik AM, Bill L, Langfrits CS, Moller AM. Is day surgery safe? A Danish multicentre study of morbidity after 57,709 day surgery procedures. Acta Anaesthesiol Scand. 2012 Mar;56(3):323-31. doi: 10.1111/j.1399-6576.2011.02631.x.
citation: Dallas KB, Froylich D, Choi JJ, Rosa JH, Lo C, Colon MJ, Telem DA, Divino CM. Laparoscopic versus open inguinal hernia repair in octogenarians: a follow-up study. Geriatr Gerontol Int. 2013 Apr;13(2):329-33. doi: 10.1111/j.1447-0594.2012.00902.x. Epub 2012 Jun 21.
Clinical trial NCT02314078: Audit of the Response Time of the Anaesthetic and Surgical Techniques for Crash Caesarean Section
Official title: Audit of the Response Time of the Anaesthetic and Surgical Techniques for Crash Caesarean Section
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pregnancy
Anaesthesia
Keywords: Caesarean section
Emergency
Anaesthesia
Lead sponsor: KK Women's and Children's Hospital
Sponsor class: OTHER_GOV
First posted: 2014-12-10
Enrollment: 390
Sex: FEMALE
Minimum age (years): 21
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Women who underwent category one Caesarean section between 2010 to 2013 at KK Women's and Children's Hospital, Singapore.

Brief summary: A decision-to-delivery interval of 30 minutes for category-1 Caesarean section deliveries is the standard of practice recommended by clinical guidelines.

Detailed description: Our institution established a protocol for category-1 ('crash') CS to expedite deliveries. This retrospective audit evaluated all women who underwent category-1 CS in KK Women's and Children's Hospital from 2010 to 2013.

Eligibility criteria: Inclusion Criteria:

* Category One Caesarean Section at KK Women's and Children's Hospital, Singapore between 2010 to 2013.

Exclusion Criteria:

* No specific exclusion criteria, retrospective audit

Primary outcomes:
measure: Decision to delivery interval
timeFrame: 1 hour
Secondary outcomes:
measure: General anaesthesia
timeFrame: 1 hour
measure: Neonatal outcome
timeFrame: 1 hour
Other outcomes:
Locations:
city: Singapore
country: Singapore
facility: KK Women's and Children's Hospital
Study officials:
affiliation: KK Women's and Children's Hospital
name: Ban L Sng, FANZCA
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00113971: Pharmacokinetics Study of Epratuzumab in Systemic Lupus Erythematosus (SLE)
Official title: A Randomized Phase II Pharmacokinetics/Pharmacodynamics Study of Epratuzumab in Patients With Systemic Lupus Erythematosus
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Lupus Erythematosus, Systemic
Keywords: study of epratuzumab in systemic lupus erythematosus
systemic lupus erythematosus
SLE
Lead sponsor: UCB Pharma
Sponsor class: INDUSTRY
First posted: 2005-06-13
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of this study is to evaluate how epratuzumab is processed by the body (pharmacokinetics) and whether 2 dose levels of epratuzumab are safe and effective in patients with SLE.

Detailed description: This study is planned to provide information on how the body processes epratuzumab and how epratuzumab affects the body when epratuzumab is given once weekly for 4 weeks in a row at one of 2 different dose levels. Additional information will be obtained related to the natural variability of disease activity in SLE patients.

Eligibility criteria: Inclusion Criteria:

* Has SLE by American College of Rheumatology revised criteria (meets \>/= 4 criteria)
* Has had SLE for at least 6 months prior to study entry
* Has at least one elevated autoantibody level at study entry
* Has moderately active SLE disease at study entry in any body/organ system (Full criteria not present here due to length of considerations. The protocols should be consulted regarding the complete list of entry criteria.)

Exclusion criteria:

* Active Severe Lupus as defined by BILAG Index Level A in any body system or organ
* Allergy to human antibodies or Murine
* Prior therapy with other anti-B cell antibodies

Primary outcomes:
measure: Evaluation of pharmacokinetic samples for epratuzumab levels and evaluation of adverse events, infusion reactions and other safety parameters.
Secondary outcomes:
measure: Evaluation of pharmacokinetic samples to assess immunogenicity and evaluation of post-treatment BILAG scores for initial efficacy and disease variability.
Other outcomes:
Locations:
city: New York
country: United States
facility: Columbia Presbyterian Medical Center
state: New York
city: Pittsburgh
country: United States
facility: Lupus Center of Excellence
state: Pennsylvania
city: Charleston
country: United States
facility: Rheumatology Associates
state: South Carolina
Study officials:
affiliation: UCB Pharma
name: Anna Barry
role: STUDY_DIRECTOR
References:
citation: Dorner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, Burmester GR. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther. 2006;8(3):R74. doi: 10.1186/ar1942. Epub 2006 Apr 21.
Clinical trial NCT06260371: National Observatory of Mycoplasma Infections in Children Under 18 Ages in France
Official title: National Observatory of Mycoplasma Infections in Hospitalized Children Under 18 Ages in France
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Mycoplasma Infections
Hospitalized Children
Lead sponsor: Association Clinique Thérapeutique Infantile du val de Marne
Sponsor class: OTHER
Collaborators: name: Groupe de Pathologies Infectieuses Pédiatriques (GPIP)
First posted: 2024-02-15
Enrollment: 3000
Sex: ALL
Minimum age (years): 1
Maximum age (years): 17
Standard ages: CHILD
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: hospitalised children under 18 age, with Mycoplasma infection

Brief summary: This study was set up because of an unusual increase in the number of cases of mycoplasma infections in France between June and November 2023.

Clinical data from children with mycoplasma infections will be collected to characterise this infection and facilitate hospital management.

Detailed description: In this study, the number of cases will be collected. In addition, we will determine the clinical, biological and microbiological characteristics of these cases.

These following data will be collected: signs or symptoms associated with this infection, clinical complications, biological and microbiological tests done during hospitalisation, treatment used during hospitalization, results of thoracic x-ray and lung ultrasound.

Eligibility criteria: Inclusion Criteria:

* Age \<18 years (only hospitalized children)
* Documented mycoplasma infection (positive multiplex PCR and/or positive serology)

Exclusion Criteria:

* Refusal by one of the parents or by Child in understanding age

Primary outcomes:
measure: Number of patients hospitalized for mycoplasma infections
timeFrame: 1 year
measure: medical characterisation of mycoplasma infections
timeFrame: 1 year
Secondary outcomes:
measure: Identify risk factors of serious infection
timeFrame: 1 year
measure: Identify predictive signs of serious infection
timeFrame: 1 year
measure: Type of complications
timeFrame: 1 year
measure: Patients outcome
timeFrame: 1 year
measure: healthcare used for infected children
timeFrame: 1 year
measure: treatment used during hospitalisation
timeFrame: 1 year
measure: clinical description of infected children
timeFrame: 1 year
measure: Type of mycoplasma involved in infected children
timeFrame: 1 year
measure: performance of complementary diagnostic tests for lung disorders
timeFrame: 1 year
measure: compare medical data collected during hospitalisation
timeFrame: 1 year
Other outcomes:
Locations:
city: Créteil
country: France
facility: ACTIV
Study officials:
affiliation: Association Clinique Thérapeutique Infantile du val de Marne
name: Corinne Levy
role: STUDY_DIRECTOR
affiliation: Hôpital Intercommunal de Villeneuve-Saint-Georges
name: Anais Chosidow
role: PRINCIPAL_INVESTIGATOR
affiliation: Hôpital des Enfants, CHU de Bordeaux
name: Emilie Pauquet
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01768871: Evaluation of the VEGA Knee System® Range of Motion
Official title: Prospective, Long-Term, Multi-Center Study on the Efficacy of the VEGA System® for Total Knee Arthroplasty.
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Patients With Total Knee Arthroplasty Using the VEGA System
Lead sponsor: Aesculap Implant Systems
Sponsor class: INDUSTRY
First posted: 2013-01-16
Enrollment: 7
Sex: ALL
Minimum age (years): 21
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who have undergone a total knee arthroplasty with the VEGA knee system®

Brief summary: The primary objective of this study is to evaluate the function of the knee after a total knee replacement with the VEGA system®.

Detailed description: To evaluate patients after total knee arthroplasty in terms of function for five years.

Eligibility criteria: Inclusion Criteria:

* willing to sign the informed consent.
* Patient has intact collateral ligaments.

Exclusion Criteria:

* Inflammatory arthritis
* Patients that have had a high tibial osteotomy or femoral osteotomy
* Patients with neuromuscular or neurosensory deficiency which would make it difficult to assess the device performance.

Primary outcomes:
measure: WOMAC
timeFrame: Two years
Secondary outcomes:
measure: Health related quality of life
timeFrame: Two years
Other outcomes:
Locations:
city: Denver
country: United States
facility: Rose Medical Center
state: Colorado
city: Vero Beach
country: United States
facility: DBA Hussamy Sports and Hand Center
state: Florida
city: Asheville
country: United States
facility: Charles J DePaolo, MD, PA
state: North Carolina
Study officials:
affiliation: Southern Illinois University School of Medicine
name: Khaled Saleh
role: STUDY_CHAIR
References:
Clinical trial NCT05801471: Clinical Evaluation of Visual Field Change in Glaucoma: an Assessment of Different Models of Progression
Official title: An Observational Prospective Longitudinal Study for the Clinical Evaluation of Visual Field Change in Glaucoma. An Assessment of Different Models of Progression
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Glaucoma
Lead sponsor: Centervue SpA
Sponsor class: INDUSTRY
First posted: 2023-04-06
Enrollment: 200
Sex: ALL
Minimum age (years): 40
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult, both males and females, 40-90 years old with diagnosis of Glaucoma

Brief summary: The purpose of this observational study is to collect over time a series of data in patients with glaucoma in order to evaluate different approaches in defining the progression of this pathology. These data will be collected in repeated visits over a 36-months follow-up period. At each visit, the COMPASS fundus perimeter and the Humphrey Field Analyzer (HFA) perimeter will be used to assess retinal functionality; an Optical Coherence Tomography (OCT) examination will also be performed to evaluate and obtain clinical information about the structure of the retina.


Eligibility criteria: Inclusion Criteria:

* Glaucomatous optic nerve head in both eyes;
* Age between 40 and 90 years;
* Best Corrected Visual Acuity ≤ 0.3 \[logMar\];
* Spherical refraction between -6D and +6D;
* Astigmatism between -2D and +2D.

Exclusion Criteria:

* Any ocular surgery, except for: uncomplicated cataract surgery and/or glaucoma surgery in both eyes performed within 6 months before enrollment;
* Any ocular pathology that can affect visual field other than glaucoma;
* Use of any drug that can interfere with the correct execution of perimetry or that would produce visual field loss;
* Inability to obtain reliable perimetric examinations;
* Patients with advanced glaucoma for whom, according to the clinician, a 24-2 grid is not advisable to correctly monitor the patient.

Primary outcomes:
measure: Equivalence between Compass and HFA in terms of estimation of the global progression rate (MD progression slope).
timeFrame: 1 visit every 4 months (10 visits total), up to 3 years
Secondary outcomes:
measure: Difference in time to identify progression between Compass and HFA using an event analysis
timeFrame: 1 visit every 4 months (10 visits total), up to 3 years
measure: Quantification of the effect of the integration of the rate of progression of structural metrics into the calculation of the rate of progression of the MD
timeFrame: 1 visit every 4 months (10 visits total), up to 3 years
Other outcomes:
Locations:
city: Milano
country: Italy
facility: Clinica oculistica Ospedale San Paolo
city: Roma
country: Italy
facility: Glaucoma Research Center, IRCCS Fondazione "G.B. Bietti"
Study officials:
affiliation: Clinica oculistica Ospedale San Paolo
name: Luca M. Rossetti, Prof.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04279171: Near-death Experience in ICU Survivors
Official title: Incidence of Near-death Experiences Among Patients Who Survived a Critical Illness
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Critical Illness
Near-Death Experience
Lead sponsor: University of Liege
Sponsor class: OTHER
First posted: 2020-02-21
Enrollment: 126
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All consecutive patients who survive any critical illness without exclusion criteria may be assessed for NDE occurence

Brief summary: This observational study aims to describe the incidence of near-death experience (NDE) in patients who survived a critical illness. In order to help determine the potential risk factors of NDE, dissociative status and spirituality are also investigated. Finally, in patients who experienced NDE, a magnetic resonance imaging is performed to search for any structural modifications.


Eligibility criteria: Inclusion Criteria:

* All consecutive patients who survived critical illness

Exclusion Criteria:

* Glasgow Coma Scale \< 15/15
* Confusion (CAM ICU scale)
* Refusal

Primary outcomes:
measure: NDE
timeFrame: Greyson questionnaire is administered during the week following ICU discharge
Secondary outcomes:
measure: Quality of life estimation
timeFrame: one year after first interview
measure: NDE
timeFrame: one year after first interview
measure: MCQ (Memory Characteristics Questionnaire)
timeFrame: one month after first interview
Other outcomes:
Locations:
city: Liège
country: Belgium
facility: University Hospital of Liège
Study officials:
affiliation: University hospital of Liège
name: Anne-Françoise Rousseau, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00592371: Head and Neck Cancer Screening and Serum Repository
Official title: Head and Neck Cancer Screening and Serum Repository
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Head and Neck Squamous Cell Cancer
Lead sponsor: University of Arkansas
Sponsor class: OTHER
First posted: 2008-01-14
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Primary Care Clinic

Brief summary: Head and Neck Squaumous Cell Cancer(HNSCC) is the 6th most common cancer in the United States and the 3rd most common worldwide. Risk factors include abuse to tobacco and alcohol. Survival is related to stage of HNSCC when treatment is sought. Most HNSCC patients present with advanced staged disease. This screening activity will educate patients with HNSCC rick factors and screen for pre malignant and/or early staged lesions.

Detailed description: Otolaryngology staff memebers and residents will perform head and neck examinations upon participants after the participant has completed their questionnaire and had the opportunity to partcipate in the research portion by having blood drawn. A suspicious head and neck examination will be considered abnormal, and further recommendations for follow-up will be made. Participants will be provided with a list of practicing head and neck surgeons within the state of Arkansas.

Eligibility criteria: Inclusion Criteria:

Exclusion Criteria:

* Under the age of 18 years of age

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Little Rock
country: United States
facility: University of Arkansas for Medical Sciences
state: Arkansas
Study officials:
affiliation: University of Arkansas
name: Brendan Stack, MD
role: PRINCIPAL_INVESTIGATOR
References: